Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma

Authors

Anthony N. Audino
Mathew J. Barth
Aradhana A. Tiwari, New York Medical College
Dina Edani, New York Medical College
Janet Ayello, New York Medical CollegeFollow
Lauren HarrisonFollow
Erin Morris
Jessica C. Hochberg, New York Medical CollegeFollow
Mitchell S. Cairo, New York Medical CollegeFollow

Author Type(s)

Faculty

Document Type

Abstract

Publication Date

2019

DOI

10.1182/blood-2019-128580

Journal Title

Blood

Department

Pediatrics

Second Department

Health Behavior and Community Health

Recommended Citation

Audino, A. N., Barth, M. J., Tiwari, A. A., Edani, D., Ayello, J., Harrison, L., Morris, E., Hochberg, J. C., & Cairo, M. S. (2019). Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma. Blood, 134 (Suppl. 1). https://doi.org/10.1182/blood-2019-128580